Gynecologic Oncology   

Questions discussed in this category

Are there certain patient subgroups for whom you would use the IO+PARPi? Is there data from DUO-E regarding BRCA status and its potential impact on ...

If yes, would you apply this broadly or reserve the addition of IO to chemotherapy for patients with high-risk histologies (e.g., carcinosarcoma) or o...

Are there patients for whom you would still reserve IO for salvage/recurrent setting (eg IO + lenvatinib)? Would you base this on MMR status or other ...

Since there is no overlap between chemo regimens for these cancers, how would you sequence treatment? 

Does the patient's MMR status affect your opinions? What is/are your current preferred second-line regimen(s)? 

Given the crossover that occurred in the various clinical trials and the potential for prolonged disease duration, how do you integrate OS, PFS, treat...

If you do not use the PORTEC-3 regimen for p53 mutated IA endometrial cancer, what specific protocol or combination of chemotherapy and radiation ther...

There is evidence that parents do not adequately understand the purpose of phase I pediatric cancer trials (Cousino et al., PMID 23071225). 

What factors influence whether you treat an elective nodal volume vs gross nodal volume (plus a small margin) in the setting of oligometastatic or oli...

Papers discussed in this category

The Journal of reproductive medicine, 2012

Gynecologic oncology, 2007-03

Int J Gynaecol Obstet,

J Immunother Cancer,

Future Sci OA, 2020 Aug 03

Cancer Treat Res Commun, 2022 Jul 01

Trends Immunol, 2021 Mar 10

Gastroenterology, 1993-06

Gastroenterology, 1991 Jul

Z Naturforsch C J Biosci, 2002 Mar-Apr

Immunopharmacol Immunotoxicol, 2003 Nov

Exp Toxicol Pathol, 2002 Feb

Biochem Biophys Res Commun, 1999 Sep 24

Ital J Gastroenterol Hepatol, 1998 Dec

Chem Biol Interact, 2001 Dec 21

Pract Radiat Oncol, 2019 Nov

Radiother Oncol, 2020 Oct 14

Brachytherapy, 2021 Dec 31

J Clin Oncol, 2019 Nov 04

J Immunother Cancer, 2022 Jan

J Clin Oncol, 2022 Jan 06

Journal of palliative medicine, 2012-11

Nature reviews. Clinical oncology, 2016-03

Int J Gynecol Cancer, 2022 Dec 20

Lancet Oncol., 2019 Jul 22

J Clin Oncol, 2020 Aug 04

Int J Gynecol Cancer, 2020 Oct 12

Gynecologic oncology, 2018-10

Int J Gynecol Cancer, 2021 Jun

J Contemp Brachytherapy, 2020 Feb 28

Lancet Oncol., 2018 Feb 12

Gynecol Oncol, 2022 Nov 15

Gynecologic oncology, 2006-10

The New England journal of medicine, 2019-06-13

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-07-20

Int J Gynecol Pathol, 2021 Jul 13

Br J Cancer, 2018 Oct 25

Lancet, 2010-03-06


Int J Radiat Oncol Biol Phys, 2023 Mar 08

Gynecol Oncol, 2020 Jul 25

The New England journal of medicine, 2016-12-01

N Engl J Med, 2022 Jan 19

J Immunother Cancer, 2022 Mar

JAMA Oncol,

Aging, 2009-12-31

Cell cycle (Georgetown, Tex.), 2010-11-15

BMC cancer, 2016-06-10

BMC Cancer, 2015 Oct 05

BMC Cancer, 2018 Apr 27

Int J Radiat Oncol Biol Phys, 2020 Jun 30

Contemporary clinical trials, 2017-02

N Engl J Med, 2023 Mar 27

N Engl J Med, 2023 Mar 27

Journal of clinical oncology : Official Journal of the American Society of Clinical Oncology, 2023 Oct 21

The New England journal of medicine, 2012-04-12

The Lancet. Oncology, 2017-01

N Engl J Med, 2019 Dec 19